Expanding targeted therapy to NRAS-mutated melanoma
- PMID: 23414591
- DOI: 10.1016/S1470-2045(13)70054-8
Expanding targeted therapy to NRAS-mutated melanoma
Comment on
-
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.Lancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414587 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous